Seeking Alpha

Roche Holding Ltd ADR (RHHBY)

  • Mon, Feb. 9, 4:01 PM
    • Roche (OTCQX:RHHBY -2.5%) acquires Potsdam, Germany-based Signature Diagnostics AG, a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers that are constructed from multicenter prospective clinical studies. Signature uses its biobank samples with clinical progression and genetic data to develop and validate circulating cell-free DNA (cfDNA) tests, which show promise in non-invasive treatment response monitoring.
    • Roche intends to leverage Signature's expertise in cancer biobanks and next generation sequencing (NGS) assay development to accelerate the development of targeted NGS-based diagnostics.
    • Specific terms of the deal are undisclosed.
    | Comment!
  • Fri, Jan. 16, 6:14 AM
    • Looking to gain access to an experimental drug to treat spinal muscular atrophy, Roche (OTCQX:RHHBY) has agreed to buy privately-held Trophos.
    • The acquisition is the latest in a spate of deals by Roche, following its purchase of a $1B stake in Foundation Medicine and licensing agreement with Genome pioneer J. Craig Venter.
    • Under the terms of the agreement with Trophos, the French firm's shareholders will receive an upfront payment of €120M ($140M), plus further payments based on predetermined milestones worth up to €350M.
    • OTCQX:RHHBY -2.2% premarket
    | Comment!
  • Mon, Jan. 12, 2:14 AM
    • Roche (OTCQX:RHHBY) is acquiring a majority of Foundation Medicine (NASDAQ:FMI) for more than $1B, by buying a combination of outstanding and newly issued shares for a 52.4%-56.3% stake on a fully diluted basis.
    • Foundation is the leader in the growing area of sequencing the genes of tumor samples, looking for mutations that can help predict which drug will be most effective for a particular patient.
    | Comment!
  • Dec. 2, 2014, 7:10 AM
    • Roche (OTCQX:RHHBY) acquires privately-held San Jose, CA-based Ariosa Diagnostics for an undisclosed sum. Ariosa provides molecular diagnostic testing services, principally non-invasive prenatal testing using cell-free DNA technology.
    • The company's Harmony Prenatal Test measures fetal cell-free DNA from a sample of the mother's blood. It is designed to assess the risk of Down syndrome.
    | Comment!
  • Nov. 24, 2014, 8:40 AM
    • Tetraphase Pharmaceuticals (NASDAQ:TTPH) is reportedly considering selling itself after being approached by interested suitors. Sources say the acquirer could be Acetelion (OTCPK:ALIOF) (OTC:ALIOY) or Roche (OTCQX:RHHBY).
    • The attraction is Tetraphase's antibiotic eravacycline, currently in Phase 3 development. Both oral and IV formulations of the drug have demonstrated higher dose response rates than Johnson & Johnson's (NYSE:JNJ) Levaquin (levofloxacin) for the treatment of complicated urinary tract infections. In the Ignite-2 study, patients receiving 200 mg eravacycline IV-to-oral doses achieved a response rate of 70.8% while patients receiving 250 mg IV-to-oral doses achieved 64.3%, both significantly ahead of Levaquin's 52.2% response rate.
    • A trial comparing eravacycline to Merck's (NYSE:MRK) Invanz (ertapenem) for the treatment of complicated intra-abdominal infections is underway.
    • TTPH is up 18% premarket on light volume.
    • Previously: Tetraphase completes eravacycline Phase 3 enrollment
    | Comment!
  • Aug. 25, 2014, 7:12 AM
    • Shares of Chugai Pharmaceutical Co. dropped over 9% on the Tokyo exchange after Roche (OTCQX:RHHBY) decided to spend its money on InterMune (NASDAQ:ITMN) instead. According to Chugai, "it is in no way in the process of reviewing any plan to become a wholly owned subsidiary of Roche."
    | Comment!
  • Aug. 24, 2014, 5:31 PM
    • Roche (OTCQX:RHHBY, OTCPK:RHHBF) will pay $74/share for InterMune (NASDAQ:ITMN), a 38% premium to its Friday close and 63% higher than Aug. 12 when news of a potential sale emerged.
    • The deal gives Roche access to pirfenidone, which targets idiopathic pulmonary fibrosis, a disease that causes tissue deep in the lungs to become thick and scarred over time. Analysts predict pirfenidone will generate $1B in global sales by 2019.
    • Pirfenidone joins Roche’s stable of pulmonary treatments, including Pulmozyme for cystic fibrosis, Xolair for asthma, and in-development asthma drug lebrikizumab. Roche plans to speed pirfenidone’s U.S. start-up and help get insurance coverage for the medicine.
    • Press release
  • Aug. 18, 2014, 4:55 PM
    • According to the WSJ's Helen Thomas, Roche's (OTCQX:RHHBY +0.7%) reported interest in spending $10B for the 40% of Chugai Pharmaceutical it doesn't own reflects more on what's not out there than what is. The lack of attractive acquisition candidates due to bullish valuations, in Roche's view, means that it makes more sense deploy its money into a known quantity. In other words, it doesn't want to overpay for a new company that fails to reach its potential.
    • Chugai's shares are no bargain, either, so Roche's timing is surprising if, indeed, it decides to make the move. Ms. Thomas thinks Roche's substantial cash horde may burning a hole in its corporate pocket. A special dividend to shareholders appears unlikely.
    | Comment!
  • Aug. 18, 2014, 4:18 AM
    • Despite Chugai Pharmaceutical (OTCPK:CHGCY) denying a rumor on Saturday of a Roche (OTCQX:RHHBY) takeover, Chugai shares jumped 15% to close at ¥3,825 on the Tokyo Stock Exchange, recording the stock's largest advance in more than 14 years.
    • Sources say Roche will acquire the 38% stake of Chugai stock it does not already own for $10B, although the company says it is not even discussing the idea with Roche.
    | Comment!
  • Aug. 17, 2014, 8:12 AM
    • Chugai Pharmaceutical (OTCPK:CHGCY) denies a rumor that surfaced Friday, which stated that Roche (OTCQX:RHHBY) was in talks to buy the 40% stake of Chugai that it does not already own for $10B.
    • The media report "is not based on any announcement made by Chugai or Roche," says the Japanese company in a news release.
    • Previously: Roche may gobble up the rest of Chugai
    | Comment!
  • Aug. 15, 2014, 12:47 PM
    • Roche (OTCQX:RHHBY -0.8%) is reportedly mulling the acquisition of the 40% of Chugai Pharmaceutical Co. it doesn't currently own for $10B. The deal could be announced as early as next week.
    • Roche established its stake in the Japanese firm in 2002.
    | Comment!
  • Aug. 13, 2014, 1:25 PM
    • Shares of InterMune (ITMN +14.3%) spike on a 2x surge in volume in response to rumors that Roche (OTCQX:RHHBY +0.4%), Sanofi (SNY +0.7%), Glaxo (GSK -0.1%) and Actelion (OTCPK:ALIOF) (OTC:ACIOY) are preparing offers. Trading in ITMN shares was halted briefly at 1:00 pm EDT due to abnormal volatility.
    | 1 Comment
  • Aug. 4, 2014, 11:47 AM
    • Roche (OTCQX:RHHBY -0.6%) agrees to acquire Copenhagen-based Santaris Pharma for an upfront fee of $250M in cash and up to $200M in development-related milestone payments.
    • Santaris' proprietary Locked Nucleic Acid platform enables the development of RNA-targeting therapeutics.
    • The transaction is expected to close this month.
    | Comment!
  • Jul. 14, 2014, 12:23 PM
    • In an interview with TheStreet's Adam Feuerstein, David Miller elaborates on his view that Roche (RHHBY +1.3%) has a strong incentive to acquire Exelixis (EXEL +10.7%) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf (vemurafenib). He says that the combo regimen could reach peak sales of $1B and should be priced at a premium to Glaxo's (GSK -0.4%) inferior offering of Tafinlar and Mekinist. He believes it will establish itself as the standard of care as a first-line therapy for BRAF-mutated melanoma.
    • Earlier today, Roche announced positive results from a Phase 3 clinical trial where patients lived significantly longer when treated with the combo regimen compared to placebo.
    | Comment!
  • Jul. 2, 2014, 2:36 AM
    • Roche (RHHBY) has announced it will buy Seragon, a breast cancer research company, for $725M. The company may pay up to another $1B based on future performance. Seragon was spun out from Aragon Pharmaceuticals last year, when the latter was purchased for $650M by Johnson & Johnson.
    • Seragon is the second major acquisition for Roche in the last two months. The company bought Genia Technologies for up to $350M in in June.
    | Comment!
  • Jun. 12, 2014, 4:16 PM
    • Privately-held biosimilar developer Epirus Biopharmaceuticals acquires Zalicus (ZLCS +38.9%) in an all-stock deal. The post-merger firm will be named Epirus Biopharmaceuticals. Current ZLCS shareholders will own ~19% of the combined enterprise. Their proportion could go down as low as 14% if Zalicus' cash position falls below $9M at closing.
    • Epirus's pipeline includes biosimilars for Janssen's (JNJ -0.8%) Remicade, AbbVie's (ABBV -1.1%) Humira and Genentech's (RHHBY -0.6%) Avastin.
    | Comment!
Visit Seeking Alpha's
RHHBY vs. ETF Alternatives
Company Description
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and... More
Sector: Healthcare
Country: Switzerland